Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
With
Roche Pharma AG
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, ≥ 18 years of age
Rheumatoid arthritis for at least 3 months
Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent
Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks
Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.
CRP ≥ 0.6 mg/dL using a high-sensitivity assay.
Positive rheumatoid factor or positive anti-CCP antibody or both.
You may not be if
Rheumatic autoimmune disease or inflammatory joint disease, other than RA
Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
Clareo Health | A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
